Ten years’ clinical experience with biosimilar human growth hormone: a review of efficacy data
Sign Up to like & getrecommendations! Published in 2017 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s130320
Abstract: In 2006, the European Medicines Agency (EMA) approved Omnitrope® as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin®, Pfizer). Data continue to… read more here.
Keywords: growth hormone; rhgh; biosimilar rhgh; efficacy ... See more keywords
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
Sign Up to like & getrecommendations! Published in 2017 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s130909
Abstract: Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose homeostasis, and the formation of antibodies to endogenous/exogenous GH. Omnitrope® (biosimilar rhGH) was approved by the European Medicines… read more here.
Keywords: medicine; rhgh; human growth; safety ... See more keywords